ELI LILLY AND COMPANY Other Comprehensive Income, Other, Net of Tax
ELI LILLY AND COMPANY (LLY) reported Other Comprehensive Income, Other, Net of Tax of $9.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeOtherNetOfTax · last filed 2026-02-12
- ELI LILLY AND COMPANY other comprehensive income, other, net of tax for the quarter ending 2017-03-31 was $2.50M, a 96.75% decline year-over-year.
- ELI LILLY AND COMPANY other comprehensive income, other, net of tax for the quarter ending 2016-12-31 was $2.50M, a 4.17% increase year-over-year.
- ELI LILLY AND COMPANY other comprehensive income, other, net of tax for the quarter ending 2016-09-30 was $2.50M, a 4.17% increase year-over-year.
- ELI LILLY AND COMPANY other comprehensive income, other, net of tax for the quarter ending 2016-06-30 was $2.40M, a 4.35% increase year-over-year.
- ELI LILLY AND COMPANY other comprehensive income, other, net of tax for fiscal 2025 was $9.00M, a 84.21% decline from fiscal 2024.
- ELI LILLY AND COMPANY other comprehensive income, other, net of tax for fiscal 2024 was $57.00M, a 41.84% decline from fiscal 2023.
- ELI LILLY AND COMPANY other comprehensive income, other, net of tax for fiscal 2023 was $98.00M.
- ELI LILLY AND COMPANY other comprehensive income, other, net of tax for fiscal 2016 was $84.30M, a 787.37% increase from fiscal 2015.
| Period end | Other Comprehensive Income, Other, Net of Tax 3 month | Other Comprehensive Income, Other, Net of Tax 3 month as first filed | Other Comprehensive Income, Other, Net of Tax 6 month | Other Comprehensive Income, Other, Net of Tax 6 month as first filed | Other Comprehensive Income, Other, Net of Tax 9 month | Other Comprehensive Income, Other, Net of Tax 9 month as first filed | Other Comprehensive Income, Other, Net of Tax 12 month | Other Comprehensive Income, Other, Net of Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $9.00M 10-K · filed 2026-02-12 | |||||||
| 2024-12-31 | $57.00M 10-K · filed 2026-02-12 | |||||||
| 2023-12-31 | $98.00M 10-K · filed 2026-02-12 | |||||||
| 2017-03-31 | $2.50M 10-Q · filed 2017-05-01 | $5.00M derived: sum of 2 quarters · filed 2017-05-01 | $7.50M derived: sum of 3 quarters · filed 2017-05-01 | $9.90M derived: sum of 4 quarters · filed 2017-05-01 | ||||
| 2016-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $5.00M derived: sum of 2 quarters · filed 2017-02-21 | $7.40M derived: sum of 3 quarters · filed 2017-02-21 | $84.30M 10-K · filed 2017-02-21 | ||||
| 2016-09-30 | $2.50M 10-Q · filed 2016-10-28 | $4.90M derived: sum of 2 quarters · filed 2016-10-28 | $81.80M 10-Q · filed 2016-10-28 | $84.20M derived: sum of 4 quarters · filed 2017-05-01 | ||||
| 2016-06-30 | $2.40M 10-Q · filed 2016-07-28 | $79.30M 10-Q · filed 2016-07-28 | $81.70M derived: sum of 3 quarters · filed 2017-05-01 | $84.10M derived: sum of 4 quarters · filed 2017-05-01 | ||||
| 2016-03-31 | $76.90M 10-Q · filed 2017-05-01 | $79.30M derived: sum of 2 quarters · filed 2017-05-01 | $81.70M derived: sum of 3 quarters · filed 2017-05-01 | $84.00M derived: sum of 4 quarters · filed 2017-05-01 | ||||
| 2015-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $4.80M derived: sum of 2 quarters · filed 2017-02-21 | $7.10M derived: sum of 3 quarters · filed 2017-02-21 | $9.50M 10-K · filed 2017-02-21 | ||||
| 2015-09-30 | $2.40M 10-Q · filed 2016-10-28 | $4.70M derived: sum of 2 quarters · filed 2016-10-28 | $7.10M 10-Q · filed 2016-10-28 | -$48.10M derived: sum of 4 quarters · filed 2017-02-21 | ||||
| 2015-06-30 | $2.30M 10-Q · filed 2016-07-28 | $4.70M 10-Q · filed 2016-07-28 | -$50.50M derived: sum of 3 quarters · filed 2017-02-21 | -$35.90M derived: sum of 4 quarters · filed 2017-02-21 | ||||
| 2015-03-31 | $2.40M 10-Q · filed 2016-04-29 | -$52.80M derived: sum of 2 quarters · filed 2017-02-21 | -$38.20M derived: sum of 3 quarters · filed 2017-02-21 | -$18.70M derived: sum of 4 quarters · filed 2017-02-21 | ||||
| 2014-12-31 | -$55.20M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | -$40.60M derived: sum of 2 quarters · filed 2017-02-21 | -$21.10M derived: sum of 3 quarters · filed 2017-02-21 | $5.90M 10-K · filed 2017-02-21 | ||||
| 2014-09-30 | $14.60M 10-Q · filed 2015-10-30 | $34.10M derived: sum of 2 quarters · filed 2015-10-30 | $61.10M 10-Q · filed 2015-10-30 | $62.60M derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2014-06-30 | $19.50M 10-Q · filed 2015-07-30 | $46.50M 10-Q · filed 2015-07-30 | $48.00M derived: sum of 3 quarters · filed 2016-02-19 | $49.50M derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2014-03-31 | $27.00M 10-Q · filed 2015-04-30 | -$22.30M 10-Q · filed 2014-04-28 | $28.50M derived: sum of 2 quarters · filed 2016-02-19 | $30.00M derived: sum of 3 quarters · filed 2016-02-19 | $31.40M derived: sum of 4 quarters · filed 2016-02-19 | |||
| 2013-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $3.00M derived: sum of 2 quarters · filed 2016-02-19 | $4.40M derived: sum of 3 quarters · filed 2016-02-19 | $5.90M 10-K · filed 2016-02-19 | $300.00K 10-K · filed 2014-02-19 | |||
| 2013-09-30 | $1.50M 10-Q · filed 2014-10-29 | $1.90M 10-Q · filed 2013-10-30 | $2.90M derived: sum of 2 quarters · filed 2014-10-29 | $4.40M 10-Q · filed 2014-10-29 | $1.00M 10-Q · filed 2013-10-30 | |||
| 2013-06-30 | $1.40M 10-Q · filed 2014-07-28 | $900.00K 10-Q · filed 2013-07-26 | $2.90M 10-Q · filed 2014-07-28 | -$900.00K 10-Q · filed 2013-07-26 | ||||
| 2013-03-31 | -$1.80M 10-Q · filed 2014-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |